Related Experiment Videos
Induction of antitumor immunity using intercellular adhesion molecule 1 (ICAM-1) transfection in mouse glioma cells
1The Institute of DNA Medicine, Department of Neurosurgery, Jikei University School of Medicine, Tokyo, Japan. oncol-tk@po.iijnet.or.jp
Abstract:
We investigated the role of intercellular adhesion molecule 1 (ICAM-1) expression in tumorigenicity of gliomas and the antitumor effects of glioma cells genetically engineered to express ICAM- 1. Mouse glioma cells transfected with ICAM-1 grew in T-cell deficient mice but not in syngeneic mice. Vaccination with ICAM-1-transfected tumor cells markedly inhibited the growth of subcutaneously inoculated gliomas but not gliomas located in the brain. In vivo antibody ablation study revealed that CD4+ T, CD8+ T and NK cells were all required to produce the antitumor effect of SR/ICAM- 1. In this study, we demonstrated the therapeutic potential of vaccination with ICAM-1-overexpressing tumor cells for the control of the tumor growth.
Insights
Intercellular adhesion molecule 1 (ICAM-1) expression impacts glioma growth and antitumor immunity. Vaccination with ICAM-1-engineered glioma cells shows therapeutic potential for controlling tumor progression.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- Gliomas are aggressive brain tumors with limited treatment options.
- Intercellular adhesion molecule 1 (ICAM-1) plays a role in immune cell interactions.
- Understanding ICAM-1's role in glioma tumorigenicity is crucial for developing novel therapies.
Purpose of the Study:
- To investigate the influence of ICAM-1 expression on glioma cell tumorigenicity.
- To evaluate the antitumor effects of genetically engineered glioma cells overexpressing ICAM-1.
- To elucidate the immune mechanisms underlying ICAM-1-mediated antitumor responses.
Main Methods:
- Genetic engineering of mouse glioma cells to express ICAM-1.
- Tumorigenicity assays in T-cell deficient and syngeneic mice.
- Vaccination studies using ICAM-1-transfected tumor cells.
- In vivo antibody-mediated cell depletion to identify key immune cells.
Main Results:
- ICAM-1 expression inhibited glioma growth in syngeneic mice but not in T-cell deficient mice.
- Vaccination with ICAM-1-transfected cells suppressed subcutaneous glioma growth.
- Brain-located gliomas showed less response to ICAM-1 vaccination.
- CD4+ T cells, CD8+ T cells, and NK cells were essential for the observed antitumor effects.
Conclusions:
- ICAM-1 expression can modulate glioma cell behavior and immune surveillance.
- Vaccination with ICAM-1-overexpressing tumor cells holds therapeutic promise for glioma treatment.
- The antitumor effects are dependent on a robust adaptive and innate immune response.